NEW
YORK, July 7, 2023 /PRNewswire/ -- Jakubowitz
Law announces that an investigation into potential securities
fraud allegations has commenced on behalf of
shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
To be contacted by a member of our team, fill out the
form:
https://claimyourloss.com/securities/regeneron-class-action-loss-submission-form/?id=41803&from=4
Further details on the investigation: The investigation
focuses on whether the Company issued false and/or misleading
statements and/or failed to disclose information pertinent to
investors. Regeneron received a response letter from the FDA on
June 27, 2023, declining to approve
its application for an 8mg dose of aflibercept, marketed in the
U.S. as Eylea. The Company claims that the denial is due to an
ongoing review of findings at a third-party filler. Based on this
news, shares of Regeneron dropped more than 9% on the same day.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities
fraud. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/regn-fraud-alert-jakubowitz-law-is-investigating-regeneron-pharmaceuticals-inc-in-connection-with-potential-violations-of-federal-securities-laws-301871610.html
SOURCE Jakubowitz Law